Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Heberprovac
- Development stage
- Unknown
- Lead developer
- Center for Genetic Engineering and Biotechnology
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Heberprovac is a therapeutic peptide-based vaccine developed by the Cuban Center for Genetic Engineering and Biotechnology (CIGB) for the treatment of advanced and metastatic prostate cancer. The vaccine consists of a modified gonadotropin-releasing hormone (GnRH) peptide (GnRHm1) conjugated to a tetanus toxoid (TT) carrier protein, formulated with very small size proteoliposomes (VSSP) and Montanide ISA 51 VG as adjuvants. Its mechanism of action involves inducing the production of anti-GnRH antibodies, which neutralize endogenous GnRH. This neutralization prevents GnRH from stimulating the pituitary gland, thereby inhibiting the release of luteinizing hormone and follicle-stimulating hormone, ultimately leading to androgen deprivation and the reduction of serum testosterone to castrate levels.
- Brand names
- Heberprovac
- Other names
- GnRHm1-TT vaccineGnRHm-1-TT vaccineGnRHm 1-TT vaccineCIGB GnRH vaccine
02
Targets
GnRH (Gonadotropin-releasing hormone 2)
Beyond the preview
Go deeper on Heberprovac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Heberprovac.